The effect of sodium butyrate and cisplatin on expression of EMT markers

PLoS ONE

Volumn 14, Issue 1, 2019, Pages

  Mrkvicova, Alena ^a,b   Chmelarova, Marcela ^b   Peterova, Eva ^a,b   Havelek, Radim ^a   Baranova, Ivana ^b   Kazimirova, Petra ^a   Rudolf, Emil ^a   Rezacova, Martina ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTEGRIN; BETA CATENIN; BUTYRIC ACID; CISPLATIN; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; NERVE CELL ADHESION MOLECULE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR SLUG; TUMOR MARKER; UVOMORULIN; VIMENTIN; ZINC FINGER E BOX BINDING HOMEOBOX 2; ANTINEOPLASTIC AGENT; CADHERIN; CDH1 PROTEIN, HUMAN; HISTONE DEACETYLASE INHIBITOR; LEUKOCYTE ANTIGEN;

A2780 CELL LINE; A2780CIS CELL LINE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CDH1 GENE; CDH2 GENE; CONTROLLED STUDY; CPG ISLAND; CTNNB1 GENE; DNA METHYLATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; ITGA2 GENE; MMP1 GENE; MMP2 GENE; MMP9 GENE; MONOTHERAPY; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; SLUG GENE; SNAI2 GENE; SNAIL1 GENE; TIMP1 GENE; TIMP2 GENE; TRANSCRIPTION REGULATION; UPREGULATION; WESTERN BLOTTING; ZEB2 GENE; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; HISTONE CODE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BUTYRIC ACID; CADHERINS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; HISTONE CODE; HISTONE DEACETYLASE INHIBITORS; HUMANS; OVARIAN NEOPLASMS;

EID: 85060159292     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0210889     Document Type: Article

References (45)

1. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017; 14(1):9–32. https://doi.org/10.20892/j.issn.2095-3941.2016.0084 PMID: 28443200
2. Curradi M, Izzo A, Badaracco G, Landsberger N. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol. 2002; 22(9):3157–73. https://doi.org/10.1128/MCB.22.9.3157-3173. 2002 PMID: 11940673
3. Jin KL, Pak JH, Park JY, Choi WH, Lee JY, Kim JH, et al. Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues. Journal of gynecologic oncology. 2008; 19(3):185–90. https://doi.org/10.3802/jgo.2008.19.3.185 PMID: 19471575
4. Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Canc Res. 2011; 30. https://doi.org/10.1186/1756-9966-30-91 PMID: 21967738
5. Koberle B, Tomicic MT, Usanova S, Kaina B. Cisplatin resistance: Preclinical findings and clinical implications. Bba-Rev Cancer. 2010; 1806(2):172–82. https://doi.org/10.1016/j.bbcan.2010.07.004 PMID: 20647037
6. Issa ME, Takhsha FS, Chirumamilla CS, Perez-Novo C, Berghe WV, Cuendet M. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma. Clin Epigenetics. 2017; 9. https://doi.org/10.1186/s13148-017-0319-5 PMID: 28203307
7. Montani MSG, Granato M, Santoni C, Del Porto P, Merendino N, D’Orazi G, et al. Histone deacetylase inhibitors VPA and TSA induce apoptosis and autophagy in pancreatic cancer cells. Cell Oncol. 2017; 40(2):167–80. https://doi.org/10.1007/s13402-017-0314-z PMID: 28160167
8. Lapinska K, Housman G, Byler S, Heerboth S, Willbanks A, Oza A, et al. The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells. Anticancer Res. 2016; 36(11):5731–42. https://doi.org/10.21873/anticanres.11156 PMID: 27793894
9. Koprinarova M, Markovska P, Iliev I, Anachkova B, Russev G. Sodium butyrate butyrate enhances the cytotoxic effect of cisplatin by abrogating the cisplatin imposed cell cycle arrest. Bmc Mol Biol. 2010; 11. https://doi.org/10.1186/1471-2199-11-49 PMID: 20576112
10. Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Frontiers in oncology. 2012; 2:33. https://doi.org/10.3389/fonc.2012.00033 PMID: 22655269
11. Kang YB, Massague J. Epithelial-mesenchymal transitions: Twist in development and metastasis. Cell. 2004; 118(3):277–9. https://doi.org/10.1016/j.cell.2004.07.011 PMID: 15294153
12. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Bio. 2014; 15(3):178–96. https://doi.org/10.1038/nrm3758 PMID: 24556840
13. Peinado H, Ballestar E, Esteller M, Cano A. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol Cell Biol. 2004; 24(1):306–19. https://doi.org/10.1128/MCB.24.1.306-319.2004 PMID: 14673164
14. Barton CA, Hacker NF, Clark SJ, O’Brien PM. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecologic oncology. 2008; 109(1):129–39. https://doi.org/10.1016/j.ygyno.2007.12.017 PMID: 18234305.
15. Kwiecinska P, Wrobel A, Tauboll E, Gregoraszczuk EL. Valproic acid, but not levetiracetam, selectively decreases HDAC7 and HDAC2 expression in human ovarian cancer cells. Toxicol Lett. 2014; 224 (2):225–32. https://doi.org/10.1016/j.toxlet.2013.10.035 PMID: 24200999
16. Kim MG, Pak JH, Choi WH, Park JY, Nam JH, Kim JH. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. Journal of gynecologic oncology. 2012; 23(3):182–9. https://doi.org/10.3802/jgo.2012.23.3.182 PMID: 22808361
17. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer. 2004; 101(12):2760–70. https://doi.org/10.1002/cncr.20709 PMID: 15536623
18. Muenyi CS, Trivedi AP, Helm CW, States JC. Cisplatin Plus Sodium Arsenite and Hyperthermia Induces Pseudo-G1 Associated Apoptotic Cell Death in Ovarian Cancer Cells. Toxicol Sci. 2014; 139 (1):74–82. https://doi.org/10.1093/toxsci/kfu029 PMID: 24519527
19. Wilkins DE, Ng CE, Raaphorst GP. Cell cycle perturbations in cisplatin-sensitive and resistant human ovarian carcinoma cells following treatment with cisplatin and low dose rate irradiation. Cancer Che-moth Pharm. 1997; 40(2):159–66. https://doi.org/10.1007/s002800050641 PMID: 9182838
20. Pani E, Stojic L, El-Shemerly M, Jiricny J, Ferrari S. Mismatch repair status and the response of human cells to cisplatin. Cell Cycle. 2007; 6(14):1796–802. https://doi.org/10.4161/cc.6.14.4472 PMID: 17622800
21. Sato T, Suzuki M, Sato Y, Echigo S, Rikiishi H. Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells. International journal of oncology. 2006; 28(5):1233–41. PMID: 16596240
22. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harbor perspectives in biology. 2009; 1(6):a003129. https://doi.org/10.1101/cshperspect.a003129 PMID: 20457567
23. Brozovic A, Duran GE, Wang YC, Francisco EB, Sikic BI. The miR-200 family differentially regulates sensitivity to paclitaxel and carboplatin in human ovarian carcinoma OVCAR-3 and MES-OV cells. Mol Oncol. 2015; 9(8):1678–93. https://doi.org/10.1016/j.molonc.2015.04.015 PMID: 26025631
24. Tian XJ, Zhang H, Xing JH. Coupled Reversible and Irreversible Bistable Switches Underlying TGF beta-induced Epithelial to Mesenchymal Transition. Biophys J. 2013; 105(4):1079–89. https://doi.org/10.1016/j.bpj.2013.07.011 PMID: 23972859
25. Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, et al. Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2013; 5 (6):1679–89. https://doi.org/10.1016/j.celrep.2013.11.034 PMID: 24360956
26. Kong D, Ahmad A, Bao B, Li Y, Banerjee S, Sarkar FH. Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. Plos One. 2012; 7(9):e45045. https://doi.org/10.1371/journal.pone.0045045 PMID: 23024790
27. Feng J, Cen J, Li J, Zhao R, Zhu C, Wang Z, et al. Histone deacetylase inhibitor valproic acid (VPA) promotes the epithelial mesenchymal transition of colorectal cancer cells via up regulation of Snail. Cell Adh Migr. 2015; 9(6):495–501. https://doi.org/10.1080/19336918.2015.1112486 PMID: 26632346
28. Giudice FS, Pinto DS, Nor JE, Squarize CH, Castilho RM. Inhibition of Histone Deacetylase Impacts Cancer Stem Cells and Induces Epithelial-Mesenchyme Transition of Head and Neck Cancer. Plos One. 2013; 8(3). https://doi.org/10.1371/journal.pone.0058672 PMID: 23527004
29. Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, et al. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Bba-Mol Cell Res. 2013; 1833(3):663–71. https://doi.org/10.1016/j.bbamcr.2012.12.002 PMID: 23246564
30. Chen X, Xiao W, Chen W, Luo L, Ye S, Liu Y. The epigenetic modifier trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial-mesenchymal transition of lens epithelial cells. Cell Death Dis. 2013; 4. https://doi.org/10.1038/cddis.2013.416 PMID: 24157878
31. Ganatra DA, Rajkumar S, Patel AR, Gajjar DU, Johar K, Arora AI, et al. Association of histone acetylation at the ACTA2 promoter region with epithelial mesenchymal transition of lens epithelial cells. Eye. 2015; 29(6):828–38. https://doi.org/10.1038/eye.2015.29 PMID: 25853442
32. Yoshikawa M, Hishikawa K, Marumo T, Fujita T. Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta 1 in human renal epithelial cells. J Am Soc Nephrol. 2007; 18(1):58–65. https://doi.org/10.1681/ASN.2005111187 PMID: 17135397
33. Lei WW, Zhang KH, Pan XC, Hu Y, Wang DM, Yuan XW, et al. Histone deacetylase 1 is required for transforming growth factor-beta 1-induced epithelial-mesenchymal transition. Int J Biochem Cell B. 2010; 42(9):1489–97. https://doi.org/10.1016/j.biocel.2010.05.006 PMID: 20580679
34. Noguchi S, Eitoku M, Moriya S, Kondo S, Kiyosawa H, Watanabe T, et al. Regulation of Gene Expression by Sodium Valproate in Epithelial-to-Mesenchymal Transition. Lung. 2015; 193(5):691–700. https://doi.org/10.1007/s00408-015-9776-9 PMID: 26286207
35. Chen CA, Chiang YC, Chang MC, Hu YH, You SL, Cheng YYK, et al. Gene methylation profiles as prognostic markers in ovarian clear cell and endometrioid adenocarcinomas. Am J Transl Res. 2015; 7 (1):139–52. PMID: 25755836
36. Boettcher M, Kischkel F, Hoheisel JD. High-Definition DNA Methylation Profiles from Breast and Ovarian Carcinoma Cell Lines with Differing Doxorubicin Resistance. Plos One. 2010; 5(6). https://doi.org/10.1371/journal.pone.0011002 PMID: 20544021
37. Sarkar S, Abujamra AL, Loew JE, Forman LW, Perrine SP, Faller DV. Histone Deacetylase Inhibitors Reverse CpG Methylation by Regulating DNMT1 through ERK Signaling. Anticancer Res. 2011; 31 (9):2723–32. PMID: 21868513
38. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CSM, et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567–76. https://doi.org/10.1038/onc.2011.611 PMID: 22249249
39. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, et al. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000; 2(2):84–9. https://doi.org/10.1038/35000034 PMID: 10655587
40. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010; 29(24):3490–500. https://doi.org/10.1038/onc.2010.102 PMID: 20418909
41. Jolly MK, Boareto M, Huang B, Jia DY, Lu MY, Ben-Jacob E, et al. Implications of the hybrid epithelial/ mesenchymal phenotype in metastasis. Frontiers in oncology. 2015; 5. https://doi.org/10.3389/Fonc.2015.00155 PMID: 26258068
42. Labrie M, St-Pierre Y. Epigenetic regulation of mmp-9 gene expression. Cell Mol Life Sci. 2013; 70 (17):3109–24. https://doi.org/10.1007/s00018-012-1214-z PMID: 23184252
43. Januchowski R, Zawierucha P, Rucinski M, Nowicki M, Zabel M. Extracellular Matrix Proteins Expression Profiling in Chemoresistant Variants of the A2780 Ovarian Cancer Cell Line. Biomed Res Int. 2014. https://doi.org/10.1155/2014/365867 PMID: 24804215
44. Nural-Guvener HF, Zakharova L, Nimlos J, Popovic S, Mastroeni D, Gaballa MA. HDAC class I inhibitor, Mocetinostat, reverses cardiac fibrosis in heart failure and diminishes CD90+ cardiac myofibroblast activation. Fibrogenesis & tissue repair. 2014; 7:10. https://doi.org/10.1186/1755-1536-7-10 PMID: 25024745
45. Lu HG, Zhan W, Yan L, Qin RY, Yan YP, Yang ZJ, et al. TET1 partially mediates HDAC inhibitor-induced suppression of breast cancer invasion. Mol Med Rep. 2014; 10(5):2595–600. https://doi.org/10.3892/mmr.2014.2517 PMID: 25175940